CD19 and systemic lupus erythematosus: In preclinical research, anti-CD19 CAR-T cell therapy has demonstrated effectiveness in removing autoreactive B cells and reducing renal IgG immunodeposition and inflammatory cell infiltration in a mouse model of SLE [71,72].